News

Nasdaq3mon
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026.
Novo Nordisk reports interim results from late-stage trial of its haemophilia A treatment
Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...
PMLiVE3mon
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in patients aged one to 11 years. The phase 3 FRONTIER3 trial initially evaluated a ...
Yahoo Finance3mon
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ... 7 February 2025 – Novo Nordisk today announced interim results ...
Pharmabiz3mon
Novo Nordisk’s phase 3 FRONTIER3 trial of once-weekly Mim8 well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
so it is encouraging to see that patients and caregivers in these analyses prefer Mim8 over their previous treatment. At Novo Nordisk, our commitment to the rare bleeding disorders community compels ...
Taiwan News3mon
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...